Juvaris BioTherapeutics, Inc. is developing adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer.
The Company's platform technology induces profound immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company's lead product candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many fold higher than other drugs in its class. JVRS-100 is in clinical development as a vaccine adjuvant and an immunotherapeutic.
Funding Rounds (5) - $63.13MUpdate
Current Team (1)Update
|Jul 23, 2015||Xconomy - With $22M Shot of Venture, Sutro Spinout Aims For Better Vaccines|
|Jan 21, 2014||SEC - SEC FORM D|
|Apr 12, 2010||OnBioVC - Juvaris BioTherapeutics raises 12500000 in venture round|
|Jan 27, 2010||FinSMEs - Juvaris BioTherapeutics raises 25000000 in venture round|
|Sep 9, 2009||Venture Beat - Juvaris BioTherapeutics raises 9000000 in grant round|
|Jul 23, 2009||Venture Beat - Cancer vaccine developer Juvaris raises $7.53M, led by Kleiner Perkins|
|Nov 20, 2007||Venture Beat - Life sciences briefing: Tuesday, Nov. 20, 2007|
|Nov 2, 2007||Venture Beat - Life sciences briefing: Friday, Nov. 2, 2007|
866 Malcolm Road
Burlingame, CA 94010